Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.48B 307M 2025-09
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Celldex Therapeutics USD 121K 609K 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Nektar Therapeutics USD 13.75M 650K 2024-06
Pfizer USD 3.54B 7.61B 2025-09
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Roche Holding CHF 22.09B 10.04B 2025-12